Abstract. In an area of intense transmission, a malaria vaccine could reduce infection due to the parasite types represented in the vaccine, but have no detectable effect on the overall frequency of infection if it did not protect against infection with heterologous parasites. These studies were performed to determine whether immunization with SPf66 decreased infection with homologous parasites containing the 11 amino acid peptide from merozoite surface protein-1 (MSP-1) in SPf66, or increased infection due to heterologous parasites containing heterologous (alternative) MSP-1 sequences. Based on this 11 amino acid peptide (YSLFQKEKMVL), three forward primers (S,Q,V) were designed to amplify the MSP-1 sequence present in SPf66, and 3 additional forward primers (G,H,I) to amplify the alternative MSP-1 sequence (YGLFHKEKMIL). This strategy was validated by polymerase chain reaction (PCR) amplification and dideoxy sequencing with 14 cloned laboratory isolates, which demonstrated that each primer amplified one MSP-1 sequence or the other, but not both. The technique was then used to examine filter paper blots from an SPf66 vaccine study of 69 subjects in Saradidi, Kenya. In that study, the prevalence of infection with YSLFQKEKMVL or YGLFHKEKMIL type parasites was unaffected by immunization with SPf66 (based on PCR amplification with the S, Q, V, G, H and I primers, respectively). These results suggest that immunization with SPf66 does not produce a selective effect in vivo. They demonstrate a molecular method to test for selection in vivo as an indirect measure of vaccine efficacy.
Between one and two million deaths result from falciparum malaria each year, 90% of which occur among children less than five years of age in sub-Saharan Africa. 1 In addition, the recent worldwide increase in the morbidity and mortality of malaria caused by drug-resistant Plasmodium falciparum has strengthened the argument for development of a malaria vaccine. 2, 3 SPf66 is a synthetic peptide vaccine candidate with the following sequence: 4, 5 
C-G-D-E-L-E-A-E-T-Q-N-V-Y-A-A-P-N-A-N-P-Y-S-L-F-Q-K-E-K-M-V-L-P-N-A-N-P-P-A-N-K-K-N-A-G-C.
The underlined sequence is from the N-terminal region of merozoite surface protein-1 (MSP-1). Within this 11 amino acid peptide there are three variable amino acids: serine (S) at the second position, which may be replaced by glycine (G) (AGT to GGT); glutamine (Q) at the fifth position, which may be replaced by histidine (H) (CAA to CAT); and valine (V) at the tenth position, which may be replaced by isoleucine (I) (GTA to ATC).
Clinical trials of SPf66 have been conducted in South America, sub-Saharan Africa, and southeast Asia, where they have involved more than 30,000 subjects. [5] [6] [7] [8] [9] [10] [11] Although there has been no evidence of serious toxicity during these studies, the efficacy of SPf66 has been controversial (ranging from Ϫ9% to ϩ74%).
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Whether immunization with SPf66 reduces morbidity and mortality or not, it should select for parasites with alternative (heterologous) MSP-1 sequences (YGLFHKEKMIL) different from the sequence in SPf66 (YSLFQKEKMVL) if it elicits an effective immune response in vivo. This effect should occur among immunized individuals, but not among unimmunized controls. To test this hypothesis, we examined blood samples from volunteers who participated in a Phase 1/2 safety, reactogenicity, and immunogenicity study of SPf66 in western Kenya during 1995.
MATERIALS AND METHODS
Study site. The Saradidi Rural Health Project includes approximately 60 villages in western Kenya with a population of 25,000 in the administrative jurisdiction of Siaya District, Nyanza Province in western Kenya. The people of Saradidi are primarily subsistence farmers of Luo ethnicity. Malaria is holoendemic in this area; its prevalence may be Ն 90% for 12 weeks or more during the rainy season (April to July or October to November) 12 with entomologic inoculation rates of 6-30 infective bites per person per month from April to August.
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Screening of volunteers. Volunteers (n ϭ 112) between 18 and 50 years of age were screened using a medical history, physical examination, and laboratory testing, including hematocrit, white blood cell count, platelet count, and malaria smear. All female volunteers had a pregnancy test within 48 hr before each immunization. Twenty-seven of the 112 volunteers were excluded for thrombocytopenia (6) , granulocytopenia (5), anemia (3), pregnancy (2), gastritis (2), abnormal liver function test results, pelvic mass, cholelithiasis, hypertension, asthma, respiratory infection, heart murmur, chest pain or because they had moved from Saradidi (1 each), leaving 85 subjects eligible for randomization. Of these 85 subjects, 27 were randomized to receive SPf66 intramuscularly, 28 to receive SPf66 subcutaneously, and 30 to receive the hepatitis B placebo.
Ethical review for issues related to human subjects and informed consent was performed at the Walter Reed Army Institute of Research (Washington, DC) and the Kenya Medical Research Institute.
Serial blood samples obtained from study subjects. One week following the second and third immunizations, volunteers received a course of quinine (10 mg/kg three times a day for three days) and doxycycline (100 mg twice a day for seven days) to eradicate parasitemia. Blood was obtained on two occasions in the month before first immunization, and weekly after the second and third immunizations, to quantify the frequency and levels of parasitemia. The blood samples included in this report were selected during discrete time periods to avoid variations in parasite populations that 
FIGURE 1. Amplification of the SPf66 region of Block 1 in merozoite surface protein-1 (MSP-1). In this semi-nested polymerase chain reaction, the first amplification is based on the universal forward and reverse primers (F and R) in conserved regions of Blocks 1 and 3. The second amplification uses one of six different forward primers, each of which is specific for S, G, Q, H, V, or I type parasites (Table 2) , and the same universal reverse primer (R) in Block 3. Dark areas represent conserved regions of Blocks 1 and 3, the clear area represents a semi-conserved region (the region of Block 1 that contains the 11 amino acid MSP-1 peptide in SPf66), and the striped area represents the variable Block 2 region. F ϭ universal 5Ј (forward) primer in Block 1 of MSP-1; S ϭ 5Ј (forward) primer specific for S at position 2; Q ϭ 5Ј (forward) primer specific for Q at position 5; V ϭ 5Ј (forward) primer specific for V at position 10; R ϭ universal 3Ј (reverse) primer in Block 3 of MSP-1. bp ϭ basepairs. may occur over time: these time periods were the month before the first immunization (February 1995), and the second and third months after second and third immunization (May-June 1995 and October-November 1995). The first parasitized blood sample in each time period was selected for polymerase chain reaction (PCR) analysis. Of the initial 85 subjects, 69 received all three immunizations with SPf66 or hepatitis B vaccine and had blood samples available at all time points for analysis.
Primer design. Three site-specific forward primers (S,Q,V) were designed within the MSP-1 fragment characteristic of MAD20 and RO33 type parasites in SPf66 (YSLFQKEKMVL) 14, 15 (Table 1 and Figure 1 ). Three additional primers were designed for the three alternative amino acids characteristic of K1 parasites (G,H,I) ( Table 1) . Each of these primers was designed with a selective mismatch at the 3Ј end so they would amplify only MAD20/RO33 or K1 type parasites. 16, 17 In addition, universal forward and reverse primers in conserved regions of Blocks 1 and 3 were designed using version 3.0 of MacDNASIS software (Hitachi, San Bruno, CA). Based on the sequences available in the GenBank Data Base, these primers had minimal homology with other known parasite or human sequences, and no evidence of hairpin loops or other secondary structure.
Extraction of DNA. Extraction of DNA from filter paper blots began with an overnight incubation in 1% saponin (Sigma, St. Louis, MO) at 4ЊC. The DNA was separated by centrifugation for 3 min at 13,000 ϫ g and ambient temperature, followed by resuspension of the filter paper in phosphate-buffered saline (PBS) with washing three times, or until all the hemoglobin was removed as indicated by a change in supernatant color from pink to clear. The DNA was then extracted from the filter paper eluate by adding 200 l of 5% (w/v) Chelex-100 in water (Bio-Rad Laboratories, Hercules, CA), followed by incubation at 56ЊC for 15 min and a second incubation at 100ЊC for 8 min. The Chelex-100 was removed by centrifugation for 3 min at 13,000 ϫ g and ambient temperature, and the DNA in the supernatant was stored at 4ЊC. Polymerase chain reaction amplification conditions. Cloned laboratory isolates were amplified directly using one of the six forward primers designed to amplify sequences containing S or G, Q or H, V or I within the 11 amino acid peptide in SPf66, together with the common reverse primer in Block 3 ( Figure 1 ). Amplification conditions for the S primer were initial denaturation at 95ЊC for 2 min, followed by 35 cycles of denaturation at 95ЊC for 15 sec, annealing at 61ЊC for 15 sec, and extension at 72ЊC for 1 min, with a final extension at 72ЊC for 5 min. For the G, Q, H, V and I primers, amplification conditions were similar except for annealing temperatures of 64Њ, 64Њ, 62Њ, 58Њ, and 57ЊC, respectively.
Field isolates were amplified initially using universal primers for the Block 1 to 3 region of MSP-1 (Figure 1 ) to increase the amount of template available for subsequent amplification with the specific 3Ј-matched and mismatched forward primers. Amplification conditions were as described above, using a semi-nested PCR strategy with specific forward primers after initial amplification with the universal forward primer. Conditions of the initial PCR were as follows: initial denaturation at 95ЊC for 2 min, followed by 35 cycles of amplification using denaturation at 95ЊC for 15 sec, annealing at 63ЊC for 15 sec, and extension at 72ЊC for 1 min, with a final extension at 72ЊC for 5 min.
Agarose gel electrophoresis and estimation of amplification product size. After amplification, the PCR products were resolved by electrophoresis on 2% agarose gels and stained with ethidium bromide (5 g/ml) . 18 The sizes of the amplified products were estimated by digitizing photographs obtained under fluorescent light using the MacDNASIS program with known controls (DNA Molecular Weight Marker V; Boehringer-Mannheim, Indianapolis, IN).
Dideoxy sequencing of PCR products. Sequencing of PCR products was performed with the Sequenase PCR product sequencing kit (Amersham, Arlington Heights, IL). First, the PCR products were treated with a combination of exonuclease I and shrimp alkaline phosphatase for 15 min at 37ЊC to remove the remaining primers and dNTPs. The exonuclease and alkaline phosphatase were then inactivated by heating at 80ЊC for 15 min. The enzyme-treated PCR products (7 l) were mixed with water (5 l) and primers (1 l). The DNA was denatured by heating at 100ЊC for 2-3 min, and then cooled on ice for 5 min. The labeling reaction mixture containing 33 P (3.5 l) was added to termination reaction tubes with G, A, T, or C and incubated at 37ЊC for 10 min. After stop solution (4 l) was added, the samples were heated at 75ЊC for 2 min before loading onto the sequencing gel (5% Long Ranger; J. T. Baker, Phillipsburg, NJ). Electrophoresis was performed for 2 hr (55 watts at Յ 45ЊC). The gel was then fixed, dried, exposed to x-ray film for 16 hr, developed, and read using the digitizer in the MacDNASIS program.
RESULTS
Validation of the PCR strategy using cloned laboratory isolates. Fourteen cloned laboratory isolates were studied to determine whether each clone yielded amplification products only with S, Q, V or G, H, I primers. After establishing that 10 clones yielded amplification products only with YSLFQKEKMVL type primers (S, Q and V), three clones only with YGLFHKEKMIL primers (G, H and I), and one clone with S, H and I primers, dideoxy sequencing was performed to determine whether these clones had DNA sequences consistent with the PCR results ( Table 2 and Figure  2 ). The results indicate that each forward primer yielded * No significant differences were observed among groups in the prevalence of infection with S, G, Q, H, V or I type parasites either before immunization with SPf66 (time point 1) or after immunization with SPf66 (time points 2 and 3). As in Table 4 , 2 values were calculated across categories at each time point and yielded the P values indicated. amplification products only with DNA from parasites containing the nucleotide sequence corresponding to that parasite type. For filter paper blots from the field, we used the universal forward and reverse primers described above for the initial PCR because they were outside the region being sequenced: the universal forward primer is in the signal sequence of MSP-1 (ϳ15 basepairs [bp] upstream from the 11 amino acid peptide of SPf66) and the reverse primer is in the conserved sequence of Block 3 (ϳ200 bp downstream from the 11 amino acid peptide of SPf66) (Figure 1) .
Effect of SPf66 on the prevalence of parasitemia. The effect of SPf66 on P. falciparum infection was studied initially by examining blood smears. If immunization with SPf66 protected against infection, one would expect a decrease in the prevalence of infection (smear positivity) among subjects receiving SPf66 intramuscularly or SPf66 subcutaneously, but not among the hepatitis B controls. These differences should have been most marked at the second and third time points. However, no such differences were observed (Table 3 ). There were also no differences in the magnitude of the parasitemia (number of asexual parasites per microliter of blood) among subjects who received SPf66 intramuscularly, SPf66 subcutaneously,or the hepatitis B placebo.
Use of PCR amplification to examine field isolates. This report examined the use of molecular techniques to distinguish infection with heterologous versus homologous parasites after immunization with SPf66. The safety, reactogenicity, and immunogenicity results from this trial will be presented elsewhere. At the time points included in the PCRbased analysis, no differences were observed among the three groups in the proportion of positive smears (Table 3) , or in the levels of parasitemia. To determine whether SPf66 reduced the frequency of subsequent infection with homologous parasites, we used the S primer to test for parasites with the homologous amino acid (serine) at position 2 of the 11 amino acid peptide from MSP-1 in SPf66 (Figure 1 ). If SPf66 reduced the frequency of subsequent infection with homologous parasites, the proportion of S type parasites at time points 2 and 3 should have been lower in the SPf66 immunized volunteers than in the controls, which was not observed (Table 4 ). Likewise, there should have been reductions in the proportion of Q and V type parasites, which were also not observed (Table 5 ). Conversely, there should have been relative increases in the proportion of G, H and I type parasites among subjects who received SPf66 (but not hepatitis B vaccine), which were also not observed (Table  5) . DISCUSSION Human trials based on clinical endpoints such as the incidence of severe disease are expensive because of the large sample sizes required to detect differences in the frequencies of such relatively rare events. This problem is exacerbated if the study must be able to detect efficacies of 30%. 9 In contrast, laboratory-based endpoints such as differences in the incidence of infection are both feasible and economical where the incidence of infection is high, as in the Saradidi region of western Kenya. However, a vaccine that prevented infection with homologous (but not heterologous) parasites might have no detectable effect on the overall incidence of infection or disease in an area with intense transmission if it did not protect against infection with heterologous parasites. Therefore, we designed the strategy described here to determine whether immunization with SPf66 has selective effects in vivo. The rationale for this strategy was that SPf66 should reduce the frequency of infection with homologous parasites if it stimulated effective humoral and cellular immune responses, even if it did not reduce the overall incidence of infection or disease.
The results presented here demonstrate that PCR amplification of DNA from filter paper blots using selectively matched (and mismatched) primers at their 3Ј ends 16, 17 can distinguish YSLFQKEKMVL from YGLFHKEKMIL P. falciparum parasites based on their sequences in Block 1 of MSP-1 ( Table 2 ). Note that the universal (forward and reverse) primers in the conserved regions of Blocks 1 and 3 used in the first step of the nested PCR should ensure that detection of unanticipated sequences did not depend on the S, Q, V, G, H or I primers, and was therefore independent of sequence variability in this region of MSP-1. 14,15 Although this strategy does depend on the forward and reverse primers in Blocks 1 and 3, there is no evidence of which we are aware for variability in those regions of Blocks 1 and 3 in MSP-1. 14,15 Thus, one important result of this work is the development of a molecular method to test for selection in vivo as an indirect measure of vaccine efficacy.
The original purpose of the field study was to examine the safety, reactogenicity, and immunogenicity of SPf66 among volunteers in a holoendemic area of sub-Saharan Africa, not to study the efficacy of SPf66 in the prevention of P. falciparum infection. Because previous studies with greater numbers of subjects (Ͼ 200 per group) have been unable to determine whether SPf66 reduced the incidence of P. falciparum infection or disease, [5] [6] [7] [8] [9] [10] [11] it is not surprising that this study (with complete data for 69 subjects [21-26 per group]) also failed to resolve that question.
If all P. falciparum parasites contained the 11 amino acid peptide of SPf66 in Block 1 of MSP-1, it would be possible to relate changes in the overall incidence of infection directly to immunization with SPf66. However, because other parasite types are also present in Kenya, a selective effect of SPf66 could be missed if infections due to heterologous parasites were more frequent among immunized subjects (even if SPf66 prevented all infections due to homologous parasites). To examine this question directly, it was necessary to distinguish parasite genotypes with different sequences in the 11 amino acid region of MSP-1 described above. To our knowledge, no strategies had been available to make this distinction prior to these studies.
The results of these studies indicate that immunization with SPf66 (containing the 11 amino acid MSP-1 sequence found in MAD20 and RO33 parasites) did not produce selective effects in vivo. It did not reduce either the frequency of infection with homologous (MAD20, RO33) parasites or select for infection with heterologous (K1) parasites in immunized subjects (Tables 3-5) . Although it has been difficult to determine whether SPf66 reduced the overall incidence of P. falciparum infection in other studies, one would expect SPf66 to reduce the incidence of infection with homologous parasites if it were an effective vaccine. However, because the number of subjects in this study was small, it has only modest statistical power (1 Ϫ ␤ ϭ 0.16). 19 Therefore, this study alone does not (and cannot) define the efficacy of SPf66. However, these results are consistent with the hypothesis that the lack of evidence for selection in vivo observed in this study of SPf66 may be responsible for the lack of efficacy observed with SPf66 in a number of clinical trials. [9] [10] [11] 
